Extracorporeal Photopheresis for Eczema: Similar Scores in a Small Trial Did Not Prove Equivalence

DOCTOR’S NOTES · ECZEMA EVIDENCE

Extracorporeal photopheresis, or ECP, is a hospital-based procedure that processes a person’s blood cells outside the body. It is different from shining therapeutic light onto eczema patches. A small comparison with cyclosporine offers a useful lesson: similar observed scores are not enough to establish that two treatments are interchangeable.

What the 2014 study compared

The primary randomized crossover study enrolled 20 adults aged 20–45 with severe atopic dermatitis refractory to other treatments. Each treatment period lasted four months, with an individualized two-to-eight-week relapse interval before switching. Fifteen people completed both courses.

ECP involved a leukocyte-rich blood fraction, methoxsalen and UVA exposure before reinfusion. Visits were on two consecutive days twice monthly. This was a specialized service, not a home light device. The trial’s cyclosporine regimen was 3 mg/kg/day, a research comparison rather than a dose recommendation for a reader.

Why the confidence interval matters

Both treatments were associated with improvement, but the between-treatment estimates were uncertain. A confidence interval crossing zero includes no difference as well as potentially important differences in either direction. A nonsignificant superiority test cannot substitute for a trial designed to establish equivalence within a prespecified acceptable margin.

The paper uses the word equipotent in its title. Readers should retain the small sample and broad interval alongside that wording. It also does not compare ECP with today’s entire range of targeted treatments.

Completion was part of the result

One participant left during the later ECP course because of pregnancy. Four left during the later cyclosporine course; side effects and satisfaction with the preceding ECP course contributed. The authors also acknowledged possible carryover. A crossover design lets people contribute observations under both treatments, but it does not erase these problems.

An apparent tolerability advantage in this small experience cannot quantify rare complications or establish long-term procedural safety. The original oral psoralen approach was changed after inconsistent levels and intolerable side effects. That history should remain attached to an otherwise reassuring summary.

Make the clinic discussion practical

For someone balancing work, exercise and repeated appointments, ask about the full treatment pathway: why a procedure is being considered, expected outcomes, venous access, visit time, monitoring, alternatives and stopping criteria. Distinguish the number of visits from the duration of a treatment course. Do not replace an existing prescription plan based on a historical comparison.

The AAD guideline hub provides current treatment context. Our cyclosporine monitoring guide explains a separate question about kidney and blood-pressure checks.

Where moisture care fits

Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not the intervention in this research. These studies do not establish pediatric efficacy or infant suitability for #003. Ask a child’s clinician about a suitable moisturizer.

Continue with a related question

• How to Read an Eczema Study Without Getting Misled by Percentages
• Your Eczema Itch Score and Your Rash Score Can Tell Different Stories
• What Is SCORAD? Understanding an Eczema Severity Score

Prepared by the Dr. Arsy editorial team. Sources checked November 9, 2026. Educational content does not diagnose an individual or imply independent medical review. Cited researchers and institutions do not endorse #003. Image is an AI-created editorial product illustration, not a patient photograph or clinical result.